HALO — Halozyme Therapeutics Share News
0.000.00%
Last trade - 00:00- $13.79bn
- $15.71bn
- $1.40bn
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets
Halozyme climbs on Dutch court win against Merck's injected Keytruda
Brief: Halozyme Wins Injunction Stopping Manufacture And Sale Of Merck's Keytruda SC In Multiple European Markets
Brief: Halozyme Announces Appointment Of Jim Daly To Its Board Of Directors
U.S. STOCKS ON THE MOVE-Dynatrace, Cava Group, Halozyme Therapeutics
U.S. STOCKS ON THE MOVE-Halozyme Therapeutics, Etsy, Netflix
Halozyme Therapeutics hits fresh record after increased $1.3 bln convertible bond sale
Halozyme Therapeutics slips on $1.05 bln convertible offering plans
Halozyme Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Halozyme Q2 revenue jumps 48%, raises 2026 outlook
Brief: Halozyme Appoints David Ramsay As President Drug Delivery
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Halozyme beats Q1 revenue estimates, sets $1 billion buyback
Brief: Halozyme Announces Global Collaboration And License Agreement With Gsk To Develop Subcutaneous Formulations Of Multiple Promising Oncology Targets
U.S. STOCKS ON THE MOVE-UnitedHealth, Intel, Apple
U.S. STOCKS ON THE MOVE-Apple, Intel, Alignment Healthcare